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Abstract
In the last decade, substantial efforts have been made to
identify NADþ biosynthesis inhibitors, specifically against nic-
otinamide phosphoribosyltransferase (NAMPT), as preclinical
studies indicate their potential efficacy as cancer drugs. How-
ever, the clinical activity of NAMPT inhibitors has proven
limited, suggesting that alternative NADþ production routes
exploited by tumors confer resistance. Here, we show the gene
encoding nicotinic acid phosphoribosyltransferase (NAPRT), a
second NADþ-producing enzyme, is amplified and overex-
pressed in a subset of common types of cancer, including
ovarian cancer, where NAPRT expression correlates with a
BRCAness gene expression signature. Both NAPRT and NAMPT
increased intracellular NADþ levels. NAPRT silencing reduced
energy status, protein synthesis, and cell size in ovarian and
pancreatic cancer cells. NAPRT silencing sensitized cells to
NAMPT inhibitors both in vitro and in vivo; similar results
were obtained with the NAPRT inhibitor 2-hydroxynicotinic
acid. Reducing NAPRT levels in a BRCA2-deficient cancer cell
line exacerbated DNA damage in response to chemotherapeu-
tics. In conclusion, NAPRT-dependent NADþ biosynthesis
contributes to cell metabolism and to the DNA repair process
in a subset of tumors. This knowledge could be used to
increase the efficacy of NAMPT inhibitors and chemotherapy.
Cancer Res; 77(14); 3857–69. 2017 AACR.
Introduction
Alterations in cell metabolism have emerged as one of the
hallmarks of cancer that could possibly lead to new targeted
therapeutic approaches (1). A strong reliance on a sustained
biosynthesis of nicotinamide adenine dinucleotide (NADþ) is
surely tobe included among these alterations (2). Features that are
commonly encountered in cancer cells and that are thought to
underlie their need to support NADþ production include aberrant
metabolic processes, increased cell proliferation, and, perhaps
most importantly, the need to face constant NADþ consumption
byNADþ-degrading enzymes involved inDNA repair (e.g., PARP,
SIRT6; refs. 3, 4), in cell signaling (e.g., CD38; ref. 5), or in the
prevention of apoptosis (e.g., SIRT1, SIRT6; refs. 3, 6, 7). In line
with this notion and based on studies from many laboratories,
interrupting NADþ biosynthesis has been proposed as a novel
strategy in oncology, and the NADþ biosynthetic machinery is
considered as a collection of promising targets for the develop-
ment of anticancer agents (8–10). Nicotinamide phosphoribo-
syltransferase (NAMPT), the rate-limiting enzyme for NADþ
production from nicotinamide in mammalian cells, was the first
NADþ biosynthetic enzyme for which a clear potential as a cancer
target was demonstrated with predicted uses in both solid and
hematologic malignancies (9, 11–13). Unfortunately, the
NAMPT inhibitors FK866 and GMX-1777 both failed in clinical
trials (14), suggesting that alternative NADþ sources could be
available to tumors. For example, one such source is represented
by nicotinamide riboside, which is transformed into NADþ
through nicotinamide riboside kinases (NMRK1/2), instead of
through NAMPT, and which can be obtained by tumor cells
through the degradation of nicotinamidemononucleotide by the
ectocellular enzyme, CD73 (15–17).
In the attempt to identify and, possibly, overcome additional
mechanisms of resistance to NAMPT inhibitors, we investigated
here the role of nicotinic acid phosphoribosyltransferase
(NAPRT), which mediates NADþ production from nicotinic
acid (NA).
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Materials and Methods
Cell lines and reagents
OVCAR-4, OVCAR-5, OVCAR-8, Capan-1, MIA PaCa2, Phoe-
nix, and HEK293T cells were purchased from ATCC (LGC Stan-
dards S.r.l.) in March 2015. Cells were passaged for less than 6
months before resuscitation for this study. Mycoplasma testing
was routinely donewith theMycoAlertMycoplasmaDetectionKit
(Lonza Group Ltd.). Last mycoplasma testing was done in Sep-
tember 2016. Cells were characterized by DNA fingerprinting and
isozyme detection. All the cell lines were revived every 3 to 4
months. Cells were maintained in RPMI1640 medium supple-
mented with 10% FBS and antibiotics. FK866 was obtained from
the NIMH Chemical Synthesis and Drug Supply Program. Puro-
mycin, 2-hydroxynicotinic acid, and GMX-1778 were purchased
from Sigma Aldrich S.r.l.
Cell doubling time and cell size determination
Cell doubling timewas estimated as in ref. 18. For cell diameter
determination, 105 cells/well were plated in 6-well plates and
allowed to adhere for 24 hours.When cells were at a confluence of
approximately 50%, cells were trypsinized and cell diameter was
determined with a handheld cell counter (Bio-Rad TC20) or by
flow cytometry (forward scatter, FSC, determination) using a
FACSCalibur (Becton Dickinson).
Viability assay and sulforhodamine B culture dish staining
Cell viability and sulforhodamine B (SRB) dish staining were
done as described elsewhere (19).
Cell-cycle analysis
Cell-cycle analysis was performed as described elsewhere (19).
Lentiviral transduction
The lentiviral plasmids encoding for a control scr-shRNA,
and for the NAPRT-sh1-5 (plasmid ID: TRCN0000242730,
TRCN0000242729, TRCN0000242727, TRCN0000180305, and
TRCN0000242731, respectively), were purchased from Sigma-
Aldrich. Lentiviral transductions were done as described in ref. 6.
NAPRT enzymatic activity assay
The NAPRT enzymatic activity was assayed using different
concentrations of NA and PRPP, in the presence or absence of
the NAPRT inhibitor 2-HNA as described in ref. 20.
Immunoblotting
Protein lysate generation and immunoblottingwere performed
as described elsewhere (19). The following antibodies were used:
mouse anti-NAPRT (CL0665, ab211529; Abcam), anti-NAMPT
(Bethyl Laboratories), anti–poly-ADP ribose (PAR; Calbiochem;
Ab-1, mouse mAb, 10H, cod. AM80), and mouse anti–b-actin
(clone C4; Santa Cruz Biotechnology).
Protein synthesis assays
Protein synthesis was quantified by the Click-iT HPG Alexa
Fluor 488 Protein Synthesis Assay Kit (Thermo Fisher Scientific)
and flow cytometry (FACSCalibur; Becton Dickinson) according
to the manufacturer's instructions.
Cell fractionation
Mitochondria and cytosolic fractions from cells were isolated as
described elsewhere (21). Ubiquinol-Cytochrome C Reductase
CoreProtein 1 (UQCRC1), phosphofructokinase (PFK), histone 3
(H3), NAPRT, and b-actin protein expression in mitochondrial
and cytosolic fractions were detected by immunoblotting using
the following antibodies: anti-UQCRCI (Origene; TA800089),
anti-PFK, and anti-H3 antibodies (Cell Signaling Technology;
8164 and 9715, respectively).
NADþ measurement
The NADþ content of whole cells, isolated mitochondria, or
cytosolic fractions was assessed as described in ref. 22.
Confocal and light microscopy
NAPRT-EGFP cellular location andDNAdamage were detected
by confocal microscopy as described in ref. 18. The anti-gH2AX
antibody was from Millipore (Ser139, clone JBW301, cod. 05-
636) and the secondary Alexa Fluor 488–conjugated antibody
was from Jackson Immuno Research (cod. 115-546-006). gH2AX
foci were counted using ImageJ-Find Maxima (23). MitoTracker
Deep Red was from Thermo Fisher. For light microscopy, cells
were imaged at room temperature using with the 20 magnifi-
cation of a Leica DMI3000 B microscope. Images were analyzed
using Leica Application Suite v3.6.0.
Three-dimensional culture and spheroid analysis
Three-dimensional cell cultures were done as described in
ref. 24.
IHC analysis of NAPRT expression in primary ovarian cancer
Twelve random serous high-grade ovarian carcinoma (HG-
OSC), stage III FIGOwere selected fromour Institutional database
for IHC analysis of NAPRT expression (authorization CER Liguria
058REG2017). Additional methods can be found in Supplemen-
tary Methodology.
Gene set enrichment analysis
We utilized a public gene expression dataset GSE40595 (25) to
explore the pathways potentially regulated by NAPRT. We ranked
epithelial ovarian cancer samples by their median NAPRT expres-
sion levels and then compared their gene expression. GSEA v2.0
(http://www.broad.mit.edu/gsea) was used to identify signifi-
cantly enriched pathways (26). Gene sets were downloaded from
the Broad Institute's MSigDB (http://www.broadinstitute.org/
gsea/index.jsp) and from ref. 27.
Animal experiments
All animal studies were conducted in accordance with the
Institutional Animal Care and Use Committee of the Ospedale
Policlinico San Martino, I.R.C.C.S. per l'Oncologia. Six- to 8-
week-old female BALB/c athymic (nuþ/nuþ)micewere purchased
fromCharles Rivers Laboratories. Mice were housed in air-filtered
laminar flow cabinets with a 12-hour light cycle and food and
water ad libitum. Mice were acclimatized for 1 week. In the
subcutaneous tumor xenograft models, 5  106 OVCAR-5 or
OVCAR-8, or 2  106 Capan-1 cells engineered to express the
control scr-shRNA or the NAPRT-sh2, or 3.5  106 MIA PaCa2
cells transduced with the vector pBP or with pBP-NAPRT were
injected subcutaneously. Treatment was initiated when the
tumors appeared as established palpable masses. In each exper-
iment,micewere randomly assigned to be treated for 3weekswith
either vehicle or FK866 (20 mg/kg i.p. twice-a-day for 4 conse-
cutive days every week). Additional methods can be found in
Supplementary Materials and Methods.
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Statistical analyses
All experiments were repeated at least 3 times. Statistical
analyses were performed with GraphPad Prism software version
5 (GraphPad Software). All parameters were tested by paired t test
or one-way ANOVA followed by Tukey test. P values < 0.05 were
considered significant.
Results
NAPRT is overexpressed in a subset of common human solid
tumors
We reasoned that the low efficacy of NAMPT inhibitors in
patients (14) could reflect the expression by tumors of enzymes
that mediate NADþ biosynthesis from precursors other than
nicotinamide. If that were the case, a tumor's NADþ pool could
be replenished regardless of NAMPT inhibition (17). Aside for
nicotinamide, the main NADþ precursors for mammalian cells
are represented by the amino acid tryptophan (which is utilized in
the so-called de novo NADþ biosynthesis pathway), by NA (uti-
lized in the Preiss–Handler pathway of NADþ biosynthesis), and
bynicotinamide riboside (17). The rate-limiting reactions in these
NADþbiosynthetic routes are catalyzedbyquinolinate phosphor-
ibosyltransferase (QPRT), NAPRT, and NMRK1/2, respectively
(17). To gain insight into the expression of these enzymes in
human cancer, we used the cBioCancerGenomics Portal, an open
platform that allows exploring multidimensional cancer geno-
mics data (28, 29). QPRT, NAPRT, and NMRK1/2 all showed a
tendency to be amplified in at least one cancer study (Fig. 1A;
Supplementary Fig. S1A). However, among the four enzymes,
NAPRT exhibited the most striking frequency of amplification:
>25% of the cases of ovarian, pancreatic, and prostate cancer, and
>10% of breast, liver, esophagus, and head and neck cancer (Fig.
1A). NAPRT was normally amplified in a nonmutated form, and
its amplification was typically associated to a marked increase in
gene expression (Fig. 1B; Supplementary Fig. S1B–S1E). Figure 1C
shows NAPRT expression and hematoxylin–eosin staining in a
series of 12primary epithelial ovarian cancers thatwere referred to
our Institution. Consistent with the data from the cBio Cancer
Genomics Portal, in this series, four cases were found to express
high NAPRT levels (mean histology score, H-score, >120), seven
cases exhibited low NAPRT expression (mean H-score <50),
whereas one case had medium NAPRT expression (mean H-score
¼ 100). Additional IHC studies of NAPRT in ovarian cancer,
as well as in other types of cancer, can be found in the
Human Protein Atlas database (http://www.proteinatlas.org/
ENSG00000147813-NAPRT/tissue; refs. 30, 31). Interestingly, by
using theNCI-60ProteomeResource (32),we verified that among
all of the cell lines fromNCI-60 cell line panel, the ovarian cancer
cell lines were those expressing the highest NAPRT levels (prote-
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NAPRT is commonly amplified andoverexpressed in solid tumors.A andB,NAPRTgenemutations, deletions, amplifications, andmultiple alterations in human cancer
(A), and NAPRT gene expression in ovarian cancer (B) as shown by the cBioPortal for Cancer Genetics (http://www.cbioportal.org/). In A, the cBioPortal
for Cancer Genetics search engine was set to highlight studies in which NAPRTwas altered in at least 5% of the tumors. C,NAPRT IHC and hematoxylin–eosin (H&E)
staining in 12 ovarian cancer specimens. H-sc., histology score.
NAPRT in Cancer Cell Metabolism and Drug Resistance
www.aacrjournals.org Cancer Res; 77(14) July 15, 2017 3859
on June 10, 2019. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 15, 2017; DOI: 10.1158/0008-5472.CAN-16-3079 
emerged as the ovarian cancer cell lines expressing the highest
NAPRT amounts.
NAPRT-overexpressing cancer cells are insensitive to FK866
We confirmed that the ovarian cancer cell lines OVCAR-5, -8,
and -4 all express both NAPRT and NAMPT (Fig. 2A and B), the
highest NAPRT amounts being typically detected in OVCAR-5. In
addition, a high NAPRT expression was also found in the pan-
creatic ductal adenocarcinoma cell line, Capan-1 (Fig. 2A and B).
We initially transduced these cell lines with two independent,
NAPRT-targeting shRNAs. Both of the shRNAs reduced NAPRT
at the mRNA and protein level, although NAPRT-sh2 was gener-
ally more effective (Fig. 2C; Supplementary Fig. S2A–S2D). Nota-
bly, no compensatory increase in NAMPT expression in response
to NAPRT silencing was detected (Supplementary Fig. S2E–S2H).
Thereafter, wemonitored total NADþ content and cell viability in
baseline conditions, in the presence of the NAMPT inhibitor,
FK866, and of NA. NAPRT silencing with NAPRT-sh2 avoided the
NA-induced increase in intracellular NADþ levels, that we
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NAPRT silencing reduces intracellular NADþ content and sensitizes ovarian cancer cells to FK866. A and B, OVCAR-5, OVCAR-4, OVCAR-8, and Capan-1 cells were
used for protein lysate generation, and NAPRT, NAMPT, and b-actin levels were determined by immunoblotting. In B, NAPRT band intensity was normalized
to b-actin expression. C, OVCAR-5 were transduced with either one of two anti-NAPRT shRNAs or with a scrambled shRNA. Cells were subsequently used for cell
lysate generation, and NAPRT and b-actin were detected by immunoblotting. D–F, 1  105 OVCAR-5, OVCAR-4, and OVCAR-8 cells expressing the scr-shRNA,
NAPRT-sh1, or NAPRT-sh2/well were plated in 6-well plates, allowed to adhere overnight, and then stimulated for 24 hours with or without 100 nmol/L FK866 in the
presence or absence of 10 mmol/L NA. Thereafter, cells were lysed in 0.6 mol/L PCA and used for NADþ determination. G–I, 2  103 scr-shRNA–, NAPRT-sh1–, or
NAPRT-sh2–expressing OVCAR-5, OVCAR-4, and OVCAR-8 cells/well were plated in 96-well plates, allowed to adhere overnight, and then incubated for
72 hours with or without FK866 at the indicated concentrations in the presence or absence of 10 mmol/L NA. Subsequently, cell viability was detected with SRB.
A–C, One representative experiment out of three is presented. D–F, Data are presented as mean  SD of three separate experiments. G–I, Data are presented
asmean of three separate experiments. ns, nonsignificant;  , P < 0.05; , P < 0.01;  , P < 0.001; #, P < 0.05; ##, P < 0.01; and ###, P < 0.001. InG–I, hashtag symbols
refer to the statistical significance of the NAPRT-sh2þNA samples.
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FK866-induced NADþ depletion (Fig. 2D–F; Supplementary Fig.
S3A). Baseline total NADþ levels were also reduced by NAPRT-
sh2, although to an extent that varied between cell lines based on
their baseline NAPRT protein levels: in OVCAR-5 and Capan-1
cells, which started with the highest NAPRT amounts (and which
were likely to be left with some residual NAPRT after silencing),
NADþ levels were only decreased by NAPRT-sh2 by 5% to 25%
(Fig. 2D; Supplementary Fig. S3A). In OVCAR-4 and OVCAR-8
cells, which had lower baseline NAPRT expression andwere likely
to be virtually devoid of this enzyme after silencing, a more
substantial decrease in NADþ could be observed (Fig. 2E and
F). Similarly, NAPRT-sh1, which was less effective in terms of
NAPRT silencing compared with NAPRT-sh2 (Fig. 2C; Supple-
mentary Fig. S2A–S2D), reducedbaselineNADþ levels inOVCAR-
4 and OVCAR-8, but not in OVCAR-5 and in Capan-1 cells
(Fig. 2D–F; Supplementary Fig. S3A). This shRNA was also gen-
erally less effective at enhancing FK866-induced NADþ depletion
compared with NAPRT-sh2 (Fig. 2D–F; Supplementary Fig. S3A).
When not combined with one another, FK866 and NAPRT
silencing both failed to affect OVCAR-4, -5, -8, and Capan-1 cell
viability (Fig. 2G–I; Supplementary Fig. S3B–S3D), which is in
line with the intracellular NADþ measurements and with pre-
vious studies showing that NADþ reductions that do not reach
90% to 95% of the basal content can be tolerated by mam-
malian cells in terms of their survival (22). However, combin-
ing NAPRT silencing by NAPRT-sh2 with FK866 resulted in a
marked reduction in cell viability in all of the cell lines tested
(Fig. 2G–I; Supplementary Fig. S3B–S3D). In addition, again
consistent with the intracellular NADþ measurements, NAPRT
silencing with NAPRT-sh2 also abolished the ability of NA
supplementation to rescue cancer cells from FK866's cytotox-
icity (Fig. 2G–I; Supplementary Fig. S3B). To rule out the
possibility that the ability of NAPRT-sh2 to sensitize NAPRT-
overexpressing cancer cells to the cytotoxic effect of FK866
could reflect off-target effects of this shRNA, we tested addi-
tional shRNAs against NAPRT, NAPRT-sh3, -4, and -5 (Supple-
mentary Fig. S3E and S3F). Using the OVCAR-5 cell model, we
found that NAPRT-sh3 and NAPRT-sh4, which, after NAPRT-
sh2, were the most effective at silencing NAPRT, also increased
the cytotoxic activity of FK866 (Supplementary Fig. S3G), albeit
to a lesser extent compared with NAPRT-sh2 (which was by far
the most active shRNA, virtually abolishing NAPRT expres-
sion). Notably, OVCAR-5 cell sensitization to GMX-1778,
another NAMPT inhibitor (33), by NAPRT-sh2, -3, and -4 was
also observed (Supplementary Fig. S3H).
Altogether, these data showed that NAPRT silencing effectively
restores the anticancer activity of NAMPT inhibitors in NAPRT-
overexpressing cancer cells. However, likely due to the fact that
NAPRT is highly effective at increasing NADþ levels (20, 34), its
near-complete knockdown is required to achieve sensitization to
FK866 and related drugs.
NAPRT reduces DNA damage and regulates cytosolic and
mitochondrial NADþ levels, oxidative phosphorylation, and
protein synthesis in cancer cells
The tumor types in which we found NAPRT to be most
commonly amplified (ovarian, pancreatic, prostate, but also
breast cancer) are also those that most frequently exhibit defects
in their homologous recombination DNA repair (HRR), a con-
dition also known as BRCAness (35). These tumors are critically
reliant on NADþ-consuming enzymes, such as PARP1/2, for their
DNA repair. Thus, we hypothesized that tumors with defective
HRR may use NAPRT-mediated NADþ production to fuel their
DNA repair mechanisms, including PARP activity. To test this
hypothesis, we assessed gene expression profiles in a set of
epithelial ovarian cancers based on their NAPRT levels, using
GSEA (26). By this approach,we found the gene expressionprofile
of BRCAness identified by Konstantinopoulos and colleagues
(27) to significantly correlate with NAPRT expression (FDR ¼
0.23; P < 0.05; Fig. 3A), whereas the KEGG DNA Damage
Response Signal Transduction gene set was found to exhibit
borderline correlation with high-NAPRT expression (FDR ¼
0.25; P ¼ 0.05; Fig. 3B). We subsequently assessed the role of
NAPRT in the susceptibility to DNA damage of Capan-1, which
are considered a model of BRCA2-deficient cancer cells (36). In
the first place, using Western blotting (37), we detected reduced
levels of PAR in NAPRT-silenced Capan-1 (Fig. 3C), which is
consistent with a reduced PARP activity. Thereafter, we found that
the alkylating agent, MMS, and the chemotherapeutic, doxoru-
bicin, caused more DNA damage in NAPRT-silenced Capan-1
than in control cells, as detected based on counts of gH2AX foci
(Fig. 3D and E). Supplementationwith exogenousNADþ reduced
MMS-mediated DNA damage in NAPRT-silenced Capan-1 (Fig.
3D and E), although with a lower efficiency compared with the
control cells. Finally, consistent with their increased predisposi-
tion to DNA damage, NAPRT-silenced Capan-1 cells showed an
impaired capacity to form colonies after a transient exposure to
MMS (Fig. 3F and G). Notably, here, even NAPRT silencing with
the less efficient shRNA, NAPRT-sh1, was sufficient to increase
Capan-1 susceptibility to MMS, suggesting that the DNA repair
process of this BRCA2-deficient cell line is critically reliant on high
NAPRT levels. Altogether, these data are in line with NAPRT
playing a role in the DNA repair mechanisms of cancer cells with
defective HRR.
We subsequently focused on the role of NAPRT in cancer cell
metabolism. In the first place, we performed subcellular fraction-
ation, isolating mitochondria and cytosol from OVCAR-4,
OVCAR-5, OVCAR-8, and Capan-1 cells expressing a control
shRNA or NAPRT-sh2, and measured the NADþ content of these
fractions. In OVCAR-4, -5, and -8 cells, NAPRT silencing reduced
both the cytosolic and the mitochondrial NADþ pools (Fig. 4A
and B). Conversely, in Capan-1 cells, only the mitochondrial
NADþ levels were blunted by NAPRT silencing, suggesting a
specific reliance of these organelles on NAPRT for the mainte-
nance of their NADþ stores. A previous study indicated that
NAPRT is primarily located in the cytosol and in the nucleus,
but not in the mitochondria (38). Consistent with this report, we
could readily detect endogenous NAPRT protein in cytosolic, but
not in mitochondrial cell fractions from OVCAR-4, -5, -8, and
Capan-1 cells (Supplementary Fig. S4A). We generated an EGFP-
tagged human NAPRT and transduced it into OVCAR-5 and
Capan-1. In these cell lines, NAPRT-EGFP exhibited a diffuse
cytoplasmic and nuclear location (Fig. 4C and D). However, no
clear mitochondrial location could be demonstrated. Thus, our
findings are in line with those of Nifikorov and colleagues (38)
and indicate that NAPRT is probably not present inmitochondria
and that NAPRT-derived nucleotides are likely to fuel the mito-
chondrial NADþ pool after import from the cytoplasm.
In subsequent experiments, we determined the effect of NAPRT
silencing with or without concomitant NAMPT inhibition with
FK866 on oxidative phosphorylation (OXPHOS), glycolysis, and
energy status of OVCAR-5 cells. Consistent with the marked
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NAPRT promotes DNA repair in cancer cells with defective HRR. A and B, The pathways potentially regulated by NAPRT were explored by GSEA in the public gene
expression data set, GSE40595. Epithelial ovarian cancer samples were ranked by their median NAPRT expression levels, and GSEA was used to identify
significantly enriched pathways. C, Capan-1 cells were transduced with NAPRT-sh2 or with scr-shRNA. Cells were subsequently used for cell lysate generation, and
PAR and b-actin were detected by immunoblotting. D and E, 2  104 Capan-1 cells transduced with a scr-shRNA or with the NAPRT-sh2/well
were plated in tissue culture chambers. Cells were allowed to adhere overnight and were subsequently treated for 1 hour with or without 1 mmol/L MMS
or 3 mmol/L doxorubicin, in the presence or absence of 100 mmol/L NADþ. Thereafter, cells were washed with PBS, fixed, permeabilized, and gH2AX foci and nuclei
(Q-nuclear) were visualized by confocal microscopy (D); scale bar, 20 mm. The number of gH2AX foci per cell/nucleus was quantified by counting at least
50nuclei per treatment condition (E).F andG, 1 103Capan-1 cells transducedwith a scr-shRNAorwith theNAPRT-sh1 or -sh2/well were plated in 6-well plates. Cells
were allowed to adhere overnight and were subsequently treated with 1 mmol/L MMS for 1 hour. Thereafter, cells were washed and incubated in regular
culturemedium for 2weeks. Finally, the plateswere stainedwith SRB and the colonies/well were counted using standardmicroscopy.C, D, and F,One representative
experiment out of three is presented. E and G, Results are mean  SD of three separate experiments. ns, nonsignificant;  , P < 0.05; and  , P < 0.001.
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reduction in the total and, especially, in themitochondrial NADþ
pool observed in NAPRT-silenced OVCAR-5, a significant
decrease in oxygen consumption rate (OCR), indicative of a
decreased oxidative metabolism, could be observed in these cells
compared with the control cells (Fig. 4E). This corresponded to a
significant reduction in ATP synthase activity (Fig. 4F). FK866 also
blunted OCR and ATP synthase activity, whereas combined
NAPRT silencing and FK866 treatment achieved the most pro-
nounced OCR and ATP synthesis reduction (Fig. 4E and F).
Notably, the P/O ratio was not affected by NAPRT silencing,
FK866, or by their combination, indicating that none of these
treatments has uncoupling effects (Supplementary Fig. S4B). The
ATP/AMP ratiowas reduced byNAPRT silencing, by FK866 and, to
the highest extent, by the two combined interventions (Fig. 4G;
Figure 4.
NAPRT regulates cytosolic and mitochondrial NADþ levels, OXPHOS, and energy status in cancer cells. A and B, 2  106 scr-shRNA– or NAPRT-sh2–expressing
OVCAR-4, OVCAR-5, OVCAR-8, and Capan-1 cells/flask were seeded in 175 cm2 flasks, allowed to grow up to 80% confluence, and subsequently used for the
isolation of mitochondria and cytosolic fractions. NADþ levels in both fractions were subsequently determined and normalized to protein content of each
fraction. C and D, OVCAR-5 and Capan-1 cells were retrovirally engineered to express a NAPRT–EGFP fusion protein. Then, NAPRT-EGFP location was
determined by confocalmicroscopy after cell stainingwith a fluorescent dye that stainsmitochondria (MitoTracker Deep Red) or a dye that stains nuclei (Q-Nuclear);
scale bars, 15 mm. E–G, 3  106 OVCAR-5 cells expressing the scr-shRNA or NAPRT-sh2/flask were seeded in 75 cm2 flasks, allowed to adhere overnight,
and then stimulated for 24 hours with or without 100 nmol/L FK866. Thereafter, cells were used for the generation of lysates in which OCR, ATP
synthase activity, aswell as ATP/AMP ratiowere determined.H,OVCAR-4, OVCAR-5, OVCAR-8, andCapan-1 cellswere analyzed by FACS for estimating their FSC as
a correlate of their volume. Note that 1  104 events per cell line were recorded. I, OVCAR-5 cells expressing either the scr-shRNA or the NAPRT-sh2 were used
for three-dimensional cultures. Ten days after cell seeding, the spheroids arising from the single cells were imaged by light microscopy and their diameter
was measured; scale bars, 100 mm. A, B, E, F, G, and I (histogram), Data are presented as mean  SD of three separate experiments. ns, nonsignificant;
 ,P<0.05;  ,P<0.01;  ,P<0.001. InE–G, the experimental values for scr-shþFK866,NAPRT-sh2, andNAPRT-sh2þFK866 all hadP<0.05 comparedwith those for
scr-sh. C, D, H, and I (photographs), One representative experiment out of three is presented.
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Supplementary Fig. S4C and S4D). Notably, the activity of gly-
colytic enzymes in cells with silenced NAPRT was not reduced. In
fact, in NAPRT-silenced OVCAR-5, increased hexokinase, phos-
phofructokinase, pyruvate kinase, and lactate dehydrogenase
activities were typically detected (Supplementary Fig. S4E–S4H).
NAPRT silencing had minor effects on the ability of cancer
cells to proliferate, because cell doubling time was only
increased by 5% to 20% in OVCAR-5, OVCAR-8, and Capan-
1 cells expressing the NAPRT-sh2 (Table 1). Cell-cycle studies of
OVCAR-5 and Capan-1 cells showed a slight reduction in the
representation of cells in the G1 phase among the NAPRT-
silenced cells (Supplementary Fig. S4I). FK866 had no effect on
the cell-cycle profile of control cells, but, consistent with the
viability data, it increased the representation of hypodiploid
nuclei (indicative of ensuing cell death) in cells expressing
NAPRT-sh2 (Supplementary Fig. S4I).
Interestingly, likely as a result of their impaired energy status,
NAPRT-silenced cells were invariably smaller compared with the
control cells as detectedbymeasurements of their diameter andby
flow cytometry (Table 1 and Fig. 4H), and this correlated with a
reduced ability to perform protein synthesis (Table 1).
In three-dimensional Matrigel cultures, both OVCAR-5 cells
expressing the control shRNA and OVCAR-5 expressing NAPRT-
sh2 gave rise to spheroids that grew gradually with a typical
spherical shape (Fig. 4I). No effect of NAPRT silencing on the
number of spheroids obtained with the two cell types could be
detected (data not shown).However, in linewith their smaller cell
size and with their slightly increased doubling time, NAPRT-sh2–
expressing OVCAR-5 gave rise to spheroids that were typically
smaller than the controls (Fig. 4I).
Therefore, in NAPRT-overexpressing cancer cells, NAPRT plays
a pivotal role in the regulation of cellular NADþ stores, OXPHOS,
energy status, protein synthesis, and cell size.
NAPRT inhibition with 2-hydroxinicotinic acid reduces
OXPHOS in NAPRT-overexpressing carcinoma cells and
sensitizes them to FK866
Previous studies indicated the ability of structural analogues of
NA to inhibit NAPRT enzymatic activity (39–41). Using the
enzymatic approach established by Galassi and colleagues
(20), we confirmed a significant inhibition of NAPRT activity by
2-hydroxinicotinic acid (2-HNA), as detected by HPLC quantifi-
cation of the NAPRT product, NA mononucleotide (Supplemen-
tary Fig. S5A–S5C). Consistentwith these data, combining 2-HNA
with FK866 in OVCAR-5 cells resulted in a more pronounced
NADþ depletion compared with FK866 alone (Fig. 5A). 2-HNA
effectively sensitized OVCAR-5 and Capan-1 cells to FK866 in
terms of cell viability (Fig. 5B and C), recreating the effect of
NAPRT silencing with NAPRT-sh2 (Fig. 2G; Supplementary Fig.
S3B), and it also sensitized OVCAR-5 cells to GMX-1778 (Sup-
plementary Fig. S5D). Similar to NAPRT silencing, 2-HNA also
reduced OCR and ATP synthase activity, which translated into a
reduction in the ATP/AMP ratio, and these effects were further
compounded by FK866 addition (Fig. 5D, E, G–I). 2-HNA,
FK866, and their combination failed to affect the P/O ratio (Fig.
5F). Finally, the effect of 2-HNA on the activity of glycolytic
enzymes mirrored that obtained by NAPRT silencing, as this
compound also increased hexokinase, phosphofructokinase,
pyruvate kinase, and lactate dehydrogenase activities (Supple-
mentary Fig. S5E–S5H).
To formally show thatNAPRToverexpression confers resistance
to FK866 to a cancer cell line that is normally sensitive to this
NAMPT inhibitor and to test the effect of 2-HNA in such amodel,
we engineered the pancreatic carcinoma cell line MIA PaCa2 to
overexpress NAPRT (Supplementary Fig. S6A). In baseline con-
ditions, MIA PaCa2 cells expressed NAPRT levels that were barely
detectable and were highly sensitive to FK866 (Supplementary
Fig. S6A–S6C). NAPRT overexpression rendered MIA PaCa2 vir-
tually completely resistant to FK866 (Supplementary Fig. S6A–
S6C). In control MIA PaCa2 cells, 2-HNA caused some sensiti-
zation to low FK866 concentrations (<10 nmol/L), but at higher
FK866 concentrations ( 10 nmol/L), it had either no or minor
activity (Supplementary Fig. S6B and S6C). Conversely, in
NAPRT-overexpressing cells, 2-HNA caused a striking sensitiza-
tion to FK866 in the entire range of FK866 concentrations tested,
fully reverting the resistance to this agent caused by NAPRT
overexpression (Supplementary Fig. S6B and S6C).
Thus, NAPRT chemical inhibition is a promising therapeutic
strategy for sensitizing NAPRT-overexpressing cancer cells to
NAMPT inhibitors.
NAPRT silencing orNAPRT inhibition sensitizes ovarian cancer
xenografts to FK866
To obtain the proof-of-concept that blocking NAPRT activity
also sensitizes NAPRT-overexpressing cancer cells to a NAMPT
inhibitor in vivo, we first generated subcutaneous xenografts of
OVCAR-5, OVCAR-8, and Capan-1 cells transduced with scr-
shRNA or NAPRT-sh2 and evaluated their response to FK866 in
terms of tumor volume and of tumor weight. In the case of
OVCAR-5 and of Capan-1 cells, only in subcutaneous xenografts
with silenced NAPRT, but not in tumors expressing the control
shRNA, FK866 reduced tumor growth (Fig. 6A–D). In OVCAR-8
xenografts, FK866 exerted some antitumor activity in both control
and NAPRT-silenced tumors. However, the antitumor effect of
FK866 was significantly more pronounced in the presence of
NAPRT silencing (Fig. 6E–G).We also tested the activity of FK866
against subcutaneous xenografts of control and NAPRT-overex-
pressing MIA PaCa2. Again, the in vivo data resembled the in vitro
results because the xenografts of control cells showed sensitivity to
FK866, but NAPRT-overexpressing MIA PaCa2 were completely
resistant (Supplementary Fig. S6D and S6E). Thereafter, we stud-
ied FK866's activity in a more clinically relevant model consisting
in the intraperitoneal injection of OVCAR-5 (control cells and
cellswith silencedNAPRT) intonudemice (42).Using thismodel,
we could not detect any effect of the NAMPT inhibitor on the








OVCAR-5 scr-sh 28 15.2 1
OVCAR-5NAPRT-sh2 30 14.1 0.7




Capan-1 scr-sh 31 15.2 1
Capan-1 NAPRT-sh2 36 14.7 0.54
NOTE: OVCAR-5, OVCAR-8, and Capan-1 cells were utilized for estimating their
doubling times, cell diameter, and protein synthesis. Within each cell line, the
Click-iT HPG signal obtained (mean fluorescence intensity as detected by flow
cytometry) was normalized to the signal produced by the same, cycloheximide-
treated cells. Thereafter, the values obtained in NAPRT-silenced cells were
normalized to those obtained in control cells (cells expressing the scrambled
shRNA).
Abbreviation: n.a., not assessed.
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survival of mice bearing control tumors (median survival of mice
with tumors expressing the scr-shRNA treated with or without
FK866 was 34.5 and 33 days, respectively; P ¼ 0.45; log rank
test; Fig. 6H and I). On the contrary, we did observe a significant
increase in mice survival when FK866 was used to treat mice
bearing tumors with silenced NAPRT (median survival of mice
with tumors expressingNAPRT-sh2 treatedwithorwithout FK866
was 45.5 and 37 days, respectively; P ¼ 0.03; log rank test; HR:
4.8). Mice with NAPRT-silenced tumors treated with FK866 also
had a better survival than mice with control tumors (scr-shRNA)
treated with or without the same agent (P¼ 0.012 and P¼ 0.007,
respectively; HR: 6.9 and 8.9, respectively). Interestingly, in mice
bearingOVCAR-5 xenograftswith silencedNAPRT, a trend toward
an increase in survival compared with mice bearing control
tumors (scr-shRNA) was also noticed, but it did not reach statis-
tical significance (P ¼ 0.14).
Given the poor solubility of 2-HNA, to be able to test the effect
of NAPRT chemical inhibition on FK866's activity in vivo, we
generated a sodium salt of 2-HNA itself (2-HNANa; Supplemen-
tary Fig. S7A), which indeed proved to be well-soluble in sterile
saline and which we found to effectively sensitize OVCAR-5
to FK866 in culture (Supplementary Fig. S7B). We intraperitone-
ally injected mice with OVCAR-5 cells and 3 days after tumor
inoculation assigned them to be treated for 3 weeks with either
vehicle, FK866, or the combination of FK866 with 2-HNANa.
Median survival of these treatment groups was 35.5, 33.5, and 42
days, respectively, with a statistically significant increase in sur-
vival versus the control group observed with the combination
Figure 5.
The NAPRT inhibitor 2-HNA sensitizes cancer cells to FK866. A, 1  105 OVCAR-5 cells were seeded in 6-cm Petri dishes, allowed to adhere overnight, and
subsequently stimulated with 100 nmol/L FK866 with or without 1 mmol/L 2-HNA. Twenty-four hours later, cell NADþ content was determined. B and C, 2  103
OVCAR-5 and Capan-1 cells/well were plated in 96-well plates, allowed to adhere overnight, and then incubated for 72 hours with or without FK866 at the
indicated concentrations in the presence or absence of 1 mmol/L 2-HNA. Subsequently, cell viability was detected with SRB. D–I, 3 106 OVCAR-5 cells/flask were
seeded in 75 cm2 flasks, allowed to adhere overnight, and then stimulated for 24 hours with or without 100 nmol/L FK866 in the presence or absence of
1mmol/L 2-HNA. Thereafter, cell lysateswere generated andOCR, ATP synthaseactivity, ATP, AMP, aswell asATP/AMPandP/O ratiosweredetermined.A,D–I,Data
are presented as mean  SD of three separate experiments. B and C, Data are mean of three independent experiments. ns, nonsignificant;  , P < 0.05; , P < 0.01;
 , P < 0.001. In A, D, E, G–I, the experimental values for FK866, 2-HNA, and FK866þ2-HNA all had P < 0.05 compared with those for vehicle.
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Figure 6.
NAPRT silencing and the NAPRT inhibitor 2-HNANa sensitize NAPRT-expressing cancer xenografts to FK866. A–G, 2  106 Capan-1 cells or 5  106 OVCAR-8 or
OVCAR-5 cells engineered to express a control scr-shRNA or NAPRT-sh2 were injected subcutaneously into nude mice. When the tumors appeared as
established palpable masses, mice (n¼ 6 per treatment arm) were randomly assigned to receive either vehicle or FK866 for 3 weeks. Tumor volume was monitored
(A, C, and E), and at sacrifice, tumor masses were excised, photographed (F), and weighted (B, D, and G). In NAPRT-sh2–expressing Capan-1, OVCAR-5,
and OVCAR-8 xenografts, FK866 reduced tumor volume by 40%, 59%, and 75%, respectively, and tumor weight by 27%, 44%, and 71%, respectively. ns,
nonsignificant;  , P <0.05;  , P <0.01;  , P <0.001.H and I,Athymicmicewere injected intraperitoneally with OVCAR-5 cells engineeredwith either a scr-shRNA or
NAPRT-sh2. Three days after tumor inoculation, mice (n ¼ 8 per treatment arm) were randomly assigned to be treated with either FK866 or vehicle DMSO
for a total of 3 weeks. H,Mice were imaged 31 days after tumor inoculation (FK866 effectively delayed ascites development only in mice with NAPRT-silent tumors).
I,Mice survival is shown.  , P < 0.05 for NAPRT-sh2þFK866 versus NAPRT-sh2þDMSO (log-rank test). J,Athymic mice were injected i.p. with OVCAR-5 cells. Three
days after tumor inoculation, mice (n ¼ 8 per treatment arm) were randomly assigned to be treated with FK866, FK866þ2-HNANa, or vehicle DMSO for
a total of 3 weeks. Mice survival is shown.  , P < 0.05 for FK866þ2-HNANa versus FK866 alone (log-rank test). K, Putative model for NAPRT's role in cancer cells.
NAPRT and NAMPT provide two parallel routes for NADþ production. While NAPRT primarily utilizes exogenous NA, whose primary source in vertebrates
are the gutmicrobial flora and the diet, NAMPT utilizes both exogenous nicotinamide (NAM) andNAMproduced inside the cells byNADþdegrading enzymes, such as
PARPs, CD38, and sirtuins. NAPRT- and NAMPT-derived NADþ replenishes cytosolic, nuclear, and mitochondrial NADþ pools and supports the activity of
DNA repair enzymes, such as PARP1/2. In NAPRT-overexpressing cancer cells, NAPRT-dependent NADþ biosynthesis appears to be especially important in
promoting OXPHOS, in themaintenance of the cellular energy status, in the regulation of protein synthesis and of cell size, and in supporting the DNA repair process.
Piacente et al.
Cancer Res; 77(14) July 15, 2017 Cancer Research3866
on June 10, 2019. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst May 15, 2017; DOI: 10.1158/0008-5472.CAN-16-3079 
FK866þ2-HNANa (P ¼ 0.033; long rank test; HR: 4.9), but not
with FK866 alone (P ¼ 0.77; Fig. 6J).
Discussion
This is the first study to show (i) that the NAPRT gene is
amplified and overexpressed in a subset of common types of
cancer; (ii) that NAPRT plays a role in cancer cell metabolism,
energy status, protein synthesis, cell size regulation, and DNA
repair; and (iii) that chemical NAPRT inhibition overcomes
resistance to NAMPT inhibitors previously tested in clinical trials.
Previous studies mainly focused on NAPRT as an enzyme,
whose absence from cancer cells could make cancer cells exqui-
sitely sensitive to NAMPT inhibitors and possibly also allow
increasing the therapeutic window of these drugs by coadminis-
tration of NA (although the value of the latter strategy has recently
been questioned; refs. 33, 43–48). Indeed, NAPRT expression
appears to be down regulated (primarily by NAPRT gene pro-
moter hypermethylation) in some types of cancer, such as soft-
tissuemalignancies, glioblastomas, andneuroblastomas (33, 47).
Nevertheless, no study has ever highlighted the fact thatNAPRT is
actually amplified and resultantly overexpressed in subsets of
other common and frequently lethal types of cancer (i.e., ovarian,
pancreatic, prostate, breast, liver, and head and neck cancers),
where it likely promotes cell metabolism and DNA repair and
reduces susceptibility to NAMPT inhibitors and to DNA-damag-
ing drugs.
Hara and colleagues showed that in human cells, NAPRT is
essential for NA to increase cellular NADþ levels and that this
enzyme canprotect cells from the toxicity ofH2O2 (34).Our study
attributes new important functions to NAPRT, showing that in
NAPRT-overexpressing cancer cells, NAPRT also contributes to the
maintenance of the intracellular NADþ pool in baseline condi-
tions. Interestingly, in Capan-1 cells, the cytosolic, but not the
mitochondrial, NADþ pool was found to be resistant to NAPRT
silencing, suggesting a specific reliance of mitochondria on
NAPRT for the replenishment of their NADþ stores. We also
demonstrate that cancer cells, in which NAPRT is silenced or
inhibited, exhibit a marked reduction in their OXPHOS and in
their ATP/AMP ratio, likely as a result of a reduction in their levels
of mitochondrial NADH, which is produced from NADþ and is
required for the activity of complex I of the electron transport
chain. Themetabolic changes resulting fromNAPRTdeletionwere
found to translate into a reduction in protein synthesis and,
ultimately, into a smaller cell size.
In epithelial ovarian cancer, we found a correlation between
high-NAPRT expression and a BRCAness gene expression pro-
file (27), and, consistent with these data, we were able to show
a role for NAPRT in the DNA repair process of the BRCA-2–
deficient cell line, Capan-1. Overall, it seems plausible that, in
ovarian cancer (and, possibly, also in other types of cancer)
with defective HRR, NAPRT amplification and the resulting
NAPRT overexpression could confer a selective advantage as
they ensure that sufficient NADþ is produced to support PARP
activity and also to protect cells from oxidative damage (34). In
line with the hypothesis that defective NADþ synthesis is
responsible for the increased DNA damage observed upon
NAPRT silencing in Capan-1, we found that exogenously added
NADþ reduced DNA damage in NAPRT-silenced cells treated
with MMS. However, interestingly, this effect was much smaller
compared with the effect of NADþ supplementation in control
cells, where NADþ addition virtually abolished MMS-induced
DNA damage. These data are not anticipated based on the
current understanding of NADþ biosynthetic routes (38),
because exogenous NADþ is thought to be degraded to yield
nicotinamide riboside, nicotinamide mononucleotide, or nic-
otinamide (but not NA), and the latter precursors should be
then reconverted into NADþ intracellularly independent of
NAPRT (38). Thus, future studies should address a possible
contribution of NAPRT to NADþ biosynthesis also starting
from such precursors.
Several points support the notion that NAPRT amplification
and its consequent overexpression represent a relevant mech-
anism of resistance to NAMPT inhibitors in humans. These
include (i) the fact that NAPRT amplification is relatively
common in human cancers, (ii) the resistance of human,
NAPRT-overexpressing ovarian and pancreatic cancer cells to
NAMPT inhibitors coupled to the fact that such resistance is
effectively abolished by NAPRT-silencing, (iii) the presence of
detectable NA levels in bodily fluids (49), and (iv) the fact that
cancer xenografts were sensitized to the anticancer effects of
FK866 if their NAPRT was either silenced or inhibited, whereas
tumor xenografts that are normally sensitive to FK866 became
resistant when overexpressing NAPRT (MIA PaCa2 model). The
latter findings indicate that tumor NAPRT can indeed also have
access to its substrate and act as a resistance mechanism to
FK866 in vivo. The use of NAPRT inhibitors appears as a
promising strategy to overcome NAPRT-mediated resistance to
NAMPT inhibitors in patients. Several compounds with inhib-
itory activity on NAPRT were previously identified, such as 2-
HNA, nucleotides, nucleosides, and intermediates of carbohy-
drates metabolism (20, 39–41). In our hands, 2-HNA proved
effective. However, because this compound has a low potency
as a NAPRT inhibitor, new NAPRT inhibitors will likely have to
be identified.
In conclusion, our study shows that NAPRT is overexpressed in
a subset of human cancer, where it contributes to themaintenance
of the NADþ stores and to promote OXPHOS, ATP production,
protein synthesis, and DNA repair (Fig. 6K). Targeting NAPRT
could prove useful for sensitizing NAPRT-expressing cancer to
NAMPT inhibitors and, possibly, to DNA-damaging agents. Our
findings broaden our understanding of the function of the NADþ
biosynthetic apparatus in cancer cells and may facilitate the
rational design of therapeutic strategies.
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